Skip to main content

Advertisement

Table 1 Patient characteristics

From: Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

   Exemestane Observation Total
Patients Number 211 200 411
Age Mean 62.6 61.8 62.2
  (range) (40–81) (39–81) (39–81)
Weight Mean 71.8 69.6 70.6
  (range) (48–100) (52–100) (48–100)
Adjuvant chemotherapy n (%)    
   No   131 (62.09) 121 (60.5) 252 (61.31)
   Yes   80 (37.91) 79 (39.5) 159 (38.69)
Local radiation therapy n (%)    
   No   77 (36.49) 82 (41.0) 159 (38.69)
   Yes   117 (55.45) 99 (49.5) 216 (52.55)
Missing data   17 (8.06) 19 (9.5) 36 (8.76)
ECOG performance status n (%)    
   0   164 (77.73) 148 (74.0) 312 (75.91)
   1   33 (15.64) 41 (20.5) 74 (18.0)
   2   1 (0.47) 0 (0.0) 1 (0.24)
   Not reported   13 (6.16) 11 (5.5) 24 (5.84)
ER and PgR status n (%)    
   ER+/PgR+   110 (52.13) 107 (53.5) 217 (52.8)
   ER+/PgR-   23 (10.9) 19 (9.5) 42 (10.22)
   ER-/PgR+   13 (6.16) 10 (5.0) 23 (5.6)
   ER+/PgR unknown   15 (7.11) 11 (5.5) 26 (6.33)
   ER and PgR unknown   50 (23.7) 53 (26.5) 103 (25.06)